You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you in comparison with other patients will actually be helped by the treatment. This is often the situation with prostate cancer, one of the deadliest and most highly prevalent cancers. While hormone therapy can help, patient responses vary widely, and it’s still unclear why some types of prostate cancer seem to be resistant to the therapy.
In work published today in Cancer Discovery, a team led by associate professor Lloyd Trotman at Cold Spring Harbor Laboratory (CSHL) shows how signalling by an immune system component called interleukin-6 (IL-6) appears to play an important role in driving particularly aggressive and therapy-resistant prostate cancer.
Read more here: